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ENCRAbstract Haematological malignancies (HM) represent over 6% of the total cancer incidence
in Europe and affect all ages, ranging between 45% of all cancers in children and 7% in the
elderly. Thirty per cent of childhood cancer deaths are due to HM, 8% in the elderly. Their
registration presents speciﬁc challenges, mainly because HM may transform or progress in
the course of the disease into other types of HM. In the context of cancer registration decisions
have to be made about classifying subsequent notiﬁcations on the same patient as the same
tumour (progression), a transformation or a new tumour registration. Allocation of incidence
date and method of diagnosis must also be standardised.
We developed European Network of Cancer Registries (ENCR) recommendations providing
speciﬁc advice for cancer registries to use haematology and molecular laboratories as data
sources, conserve the original date of incidence in case of change of diagnosis, make provision
for recording both the original as well as transformed tumour and to apply precise rules for
recording and counting multiple diagnoses. A reference table advising on codes which reﬂect
a potential transformation or a new tumour is included.Ireland,
1110 A. Gavin et al. / European Journal of Cancer 51 (2015) 1109–1122This work will help to improve comparability of data produced by population-based cancer
registries, which are indispensable for aetiological research, health care planning and clinical
research, an increasing important area with the application of targeted therapies.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Haematological malignancies (HM) represent over
6% of all cancers occurring in the European population.
It is estimated that more than 232,000 new cases of HM
occurred in forty European countries in 2012 and over
120,000 persons died of these conditions. HM aﬀect all
age groups, to a diﬀerent extent (Fig. 1). The ﬁve-year
prevalence estimate exceeds 575,000 patients [1]. Timely
and correct diagnosis is indispensable for eﬃcient dis-
ease control.
Diﬃculties arise for cancer registries in the registration
of multiple tumours, in particular, haematological malig-
nancies (HM) which may transform or progress in the
course of the disease. HM are thought to arise by genetic
change (malignant transformation) of a single cell origi-
nally present in bonemarrow, thymus or the lymphoid sys-
tem.The transformed cell undergoes clonal replication and
expansion. In many cases further genetic changes take
place and the subsequent clones become more aggressive,
or transform into a diﬀerent tumour type [2]. Examples
of transformation include myelodysplastic syndrome to
acute myeloid leukaemia. HM may be diagnosed at any
stage in the process of malignant transformation.
Better understanding of the natural history of these
diseases, together with rapid advances in methods for
diagnosis and prognosis prediction, has led to improve-
ment in HM classiﬁcation. These have been reﬂected in
updates to the International Classiﬁcation of Diseases
for Oncology [3–5]. The Haemacare manual [6] provides
useful clinical information on HM and their coding and
helps explain decision making processes. While excellent
for clinicians, it lacks the speciﬁc practical advice
required by population based or clinical registries for
registration of evolution or transformation of HM.
This work which should be considered supplementary
to the Haemacare manual and takes account of new
morphological codes [5] was undertaken by a Working
Group (WG) of Work Package 3 of Eurocourse
(www.eurocourse.org) following terms of reference pre-
pared by the Steering Committee of the European Net-
work of Cancer Registries (ENCR) to:
a) Deﬁne how cancer registries should record HM
undergoing transformation from a tumour with
uncertain behaviour (coded /1) to malignant
tumour (behaviour coded /3), or from one malig-
nant histology to another and
b) Provide rules for recording and counting multiple
diagnoses of HM in the registry database2. Methods
For this work the WG ﬁrstly reviewed the available
information on the subject. This included existing ENCR
rules [7], the Haemacare manual [6], rules for coding
multiple HM from European registries represented in
the WG (United Kingdom (UK), Spain, France, Italy
and The Netherlands), as well as the Hematopoietic and
Lymphoid Database from the Surveillance, Epidemiol-
ogy, and End Results (SEER) Program from the United
States [8]. Based on the existing information new recom-
mendations were made, as well as a list with morphology
combinations to support the decisionwhether to code one
or two HM. The latter list was based on an (unpublished)
list from the Netherlands and adapted using the expert’s
opinion of the WG members.3. Recommendations
3.1. Multiple data sources should be used to register HM
Except for lymphomas, most of the myelodysplastic
disorders, myeloproliferative neoplasms and leukaemias
may not have a solid tissue diagnosis and deﬁnitive diag-
nosis will be made on haematological preparations alone.
Therefore, in addition to histopathology, cytology, clini-
cal records and death notiﬁcations, registration of HM
requires data on blood, bone marrow, ﬂow cytometry,
molecular and cytogenetic tests from haematology and
designated molecular laboratories. These speciﬁc data
sources are required to ensure complete case ascertain-
ment and accurate morphological classiﬁcation.
As already mentioned in the Haemacare manual [6],
cytogenetic analysis is essential for establishing the diag-
nosis of subgroups of acute myeloid leukaemia (AML),
myelodysplastic syndromes (MDS) and chronic myeloid
leukaemia (CML), and for identifying other myelopro-
liferative and lymphoproliferative disorders e.g. through
the JAK-2 mutation to conﬁrm polycythaemia vera,
t(11;14) translocation to conﬁrm mantle cell lymphoma
or the t(8;14) translocation to conﬁrm Burkitt lym-
phoma. Further detail and examples of these are avail-
able in the Haemacare manual [6].3.2. Registration of multiple notiﬁcations
After a newly diagnosed haematological malignancy
has been registered, additional information obtained
Fig. 1. Haematological malignancies in Europe in 2007: age-speciﬁc incidence and mortality rates based on 73 population-based cancer registries
providing data to the EUREG database.
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options for registration.
a. Same tumour, but with a more speciﬁc or revised
diagnosis
b. Transformation
c. New tumour registration
Table 1 shows for the myelodysplastic syndromes
(MDS) potential combinations of morphology codes
that can be considered as the same tumour or a transfor-
mation. Unspeciﬁc codes are underlined. A more exten-
sive table containing all haematological malignancies is
available in the appendix. In general, diﬀerent diagnoses
within a diagnostic group of the World Health Organi-
sation (WHO) Classiﬁcation (such as MDS) will relate
to the same tumour. In all cases, the most speciﬁc diag-
nosis should be registered with clinical opinion having
the ﬁnal call. Combinations which are not in the table
can be considered as two separate tumours.3.2.1. Same tumour but with a more speciﬁc or revised
diagnosis
In HM it is not uncommon that diﬀerent diagnostic
specimens result in a diﬀerent diagnosis. In general, such
diﬀerent diagnoses within a diagnostic group of the
WHO Classiﬁcation will relate to the same tumour [4].
The most speciﬁc morphology code should be registered.
For example, if a patient’s medical ﬁle has a ‘myelo-
dysplastic syndrome’ (morphology code 9989), and the
laboratory report gives the speciﬁc diagnosis of ‘refrac-
tory anaemia with excess blasts’ (morphology code
9983), the latter morphology code should be registered,
as according to Table 1 9989/3 and 9983/3 probablyTable 1
Combinations of morphology codes of haematological malignancies (HM
combinations with myelodysplastic syndrome are shown; see the appendix
Initial diagnosis Morphology code
of the ﬁrst HM
Morphol
referring
ﬁrst HM)
Refractory anaemia 9980/3 Other my
(MDS)*,
Refractory anaemia with ring
sideroblasts
9982/3 Other MD
Refractory anaemia with excess blasts 9983/3 Other MD
Refractory cytopenia with multi-lineage
dysplasia; Refractory cytopenia of
childhood
9985/3 Other MD
Myelodysplastic syndrome associated
with isolated del(5q)
9986/3 Other MD
Myelodysplastic syndrome, therapy
related
9987/3 Other MD
Myelodysplastic syndrome, NOS 9989/3 Other MD
Refractory neutropenia 9991/3 Other MD
Refractory thrombocytopenia 9992/3 Other MD
Non-speciﬁc morphology codes are underlined, morphology codes ﬁrst int
* MDS includes the following morphology codes: 9980/3, 9982/3, 9983/3,
** AML includes the following morphology codes: 9840/3, 9861/3, 9866/3
*** MD/MPN (myelodysplastic/myeloproliferative neoplasm) includes therefer to the same tumour and 9983/3 is the most speciﬁc
code (not underlined).
When a pathological specimen/slide is reviewed by an
expert pathologist/haematologist/cytologist the expert
opinion is considered the deﬁnitive diagnosis, but the revi-
sion of the diagnosis will not change the already assigned
date of incidence. For example, if the initial diagnosis is
‘refractory anaemia’ (morphology code 9980), while after
revision the diagnosis is modiﬁed into ‘myelodysplastic
syndrome with isolated del(5q)’ (morphology code 9986),
the latter morphology code should be registered.3.2.2. Transformation
When a HM transforms into a new morphological
entity, only the ﬁrst tumour is to be considered as inci-
dent: the transformed tumour must not be counted as
a new tumour and therefore not be included in the inci-
dence statistics.
If the transformation occurs within three months
after the incidence date initially chosen, the morphology
code of the transformed malignancy should replace that
of the ﬁrst tumour and be recorded as the ﬁrst primary
and not a transformation. If the transformation occurs
outside the three month window, then the morphology
code should be recorded as that of the initial malignancy
and the morphology of the transformed malignancy,
while noted in the registry, must not be included in inci-
dence estimates.
Preferably, registries should record information on
original as well as transformed tumours. The transfor-
mation/multiple primary rules should then be applied
only at the time of analysis. The record of the trans-
formed malignancy should, if possible, also be ﬂagged
as transformation. In accordance with the Haemacare) referring to the same tumour or to a potential transformation (only
for other combinations).
ogy codes probably
to the same tumour as the
Morphology codes referring to potential
transformation of the ﬁrst HM
(see note 3)
elodysplastic syndromes
9945/3, 9975/3
Acute myeloid leukaemia (AML)**,
9801/3, 9860/3
S*, 9945/3, 9975/3 AML**, 9801/3, 9860/3
S*, 9945/3, 9975/3 AML**, 9801/3, 9860/3
S*, 9945/3, 9975/3 AML**, 9801/3, 9860/3
S*, 9945/3, 9975/3 AML**, 9801/3, 9860/3
S*, 9945/3, 9975/3 AML**, 9801/3, 9860/3
S*, MD/MPN*** AML**, 9801/3, 9860/3
S*, 9945/3, 9975/3 AML**, 9801/3, 9860/3
S*, 9945/3, 9975/3 AML**, 9801/3, 9860/3
roduced in the ICD-O-3 update of 2011 are in bold.
9985/3, 9986/3, 9987/3, 9989/3, 9991/3, 9992/3.
–9874/3, 9891/3, 9895/3–9931/3.
following morphology codes: 9876/3, 9945/3, 9946/3, 9975/3.
A. Gavin et al. / European Journal of Cancer 51 (2015) 1109–1122 1113manual [6], the following additional items are recom-
mended to be included in the cancer registry database
to accommodate the recording of transformations: Transformation yes/no
 Date of transformation dd/mm/yyyy
 Topography of transformed HM ICD-O
 Morphology of transformed HM ICD-OFor example, if six months after the diagnosis of a
refractory anaemia with excess blasts an acute myeloid
leukaemia is diagnosed, this should be considered as a
transformation, if within three month period then it
would be considered as a ﬁrst registration of acute mye-
loid leukaemia with no transformation and date of diag-
nosis that of the diagnosis of the refractory anaemia.
(see Table 1).
3.2.3. A new tumour registration
This occurs when
i. a HM with malignant behaviour (code /3) occurs
after a previous haematological disease with
uncertain behaviour (code /1) (the later diagnosed
malignant HM should be registered as a new
tumour with a new incidence date)or
ii. the change is not a transformation or a revised
diagnosis of an existing tumouror
iii. a clinical opinion regarding a new tumour is avail-
able and the details of that decision is recorded.
For example, irrespectively of the time interval
between the two diagnoses, two separate tumours
should be registered in the case of Hodgkin lymphoma
following a myelodysplastic syndrome, (the combina-
tion is not in Table 1).
3.3. Survival analysis of multiple tumours/transformations
Regular survival analysis methods do not necessarily
apply in the case of patients with HM where transforma-
tions have occurred as the patient has to be alive until
the diagnosis of multiple tumour or transformation
occurs. The information of these changes may be used
as time-dependent covariates. There are special methods
for such multiple tumour analyses [10].
3.4. The basis of diagnosis follows the ENCR
recommendations [7]
In general, code 5 (cytological examination of periph-
eral blood, bone marrow aspirate or other aspirates) andcode 7 (histology of lymph node or tissue biopsy includ-
ing trephine bone marrow biopsy) are most appropriate
for HM. Blood tests e.g. smears should be considered to
have the same standing as ‘cytology’ (code 5).
 Code 1 (physical examination, diagnosis made before
death, but without the support of diagnostic modali-
ties) and Code 6 (Histology of metastasis) are not
applicable to haematological malignancies.
 Code 4 (speciﬁc tumour marker) is applicable for
multiple myeloma diagnosed with other criteria using
data on serum immunoglobulins or light chain uri-
nary excretion.
 Code 2 (instrumental/surgical examination) may be
applicable exclusively for brain lymphoma3.5. Incidence date
The ENCR recommendations for coding of incidence
date should be followed for assigning the incidence date
for HM for the purposes of cancer registration [9].
When a pathological specimen/slide is reviewed by a
second expert pathologist, the expert opinion is consid-
ered the deﬁnitive diagnosis, but the original date of
incidence does not change.
4. Discussion
This paper provides the guidelines necessary for correct
recording of HM, so that the resulting population-based
datamaymonitor the incidence and outcomewith asmuch
precision as possible. These data inform the priorities for
clinical research as well as health policy decisions.
There are over 600 population-based cancer registries
internationally, 300 included in Cancer Incidence in V
Continents [11,12], all recording data according to agreed
rules on malignant and premalignant diseases for deﬁned
populations. Some of them specialise in registration of
HMonly, either in childhood or in all ages. They monitor
disease levels and changes over time, facilitate scientiﬁc
study of disease causes and patterns, including alleged
clusters and enable monitoring of patient care and
outcomes including survival. These cancer registries
have developed worldwide collaboration and regional
networks. Standardised data recording, processing and
reporting are indispensable for comparative studies
across populations and over time. Presented recommen-
dations are in line with the current classiﬁcation
standards, including pathological classiﬁcation of HM
covered in the WHO, Classiﬁcation of Tumours of the
Haematopoietic and Lymphoid tissue [4], the ICD-O-3
[3] and its update of 2011 [5]. TheHaemacaremanual pro-
vides useful clinical information on HM and their coding
and helps explain decision making processes [6]. The cur-
rent work will supplement the publications mentioned
above with speciﬁc practical advice for the population-
based cancer registries as well as all primary data
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1114 A. Gavin et al. / European Journal of Cancer 51 (2015) 1109–1122providers and may be useful also for clinical cancer
registries. It highlights the need for standardised rules
for registration, coding and selecting of HMs for
analyses.
Incidence statistics serves a basis for aetiological
studies, therefore only the ﬁrst incident tumour will be
most of interest. However, to allow for changes in multi-
ple primary rules over time and various research inter-
ests, it is important that the registries retain all
available data on transformed tumours or successive
diagnoses in their databases. Counting only one tumour
will also help to keep coherence with the mortality
statistics.
Inclusion of cases in the analysis of survival will
depend on the question asked. To produce population-
based estimates of survival, the ﬁrst tumour will most
often be of interest. However, data should also allow
for analysing survival of patients with speciﬁc succession
of neoplasms or transformations, using the appropriate
statistical methods.
The ENCR recommendations for recording of HM
were developed by a dedicated working group during
2012 (full report at www.encr.eu) and endorsed by the
Steering Committee of ENCR in April 2013. They com-
plement the series of ENCR recommendations on regis-
tration practices released between 1995 and 2002 [7].
Their implementation will improve the comparability
of incidence and survival data for HM across cancer reg-
istries and over time.gi
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Chronic myeloid leukaemia, BCR-ABL1
positive
9875/3 Other MPN, 9800/3, 9860/3 AML, 9811/3–9818/3, 9835/3–9837/3,
9801/3–9809/3
Polycythaemia vera 9950/3 Other MPN MDS, AML, 9801/3–9809/3
Myeloproliferative neoplasm, NOS 9960/3 OtherMPN,MD/MPN MDS, AML, 9801/3–9809/3
Primary myeloﬁbrosis 9961/3 Other MPN, 9931/3 AML (excl 9931), 9801/3–9809/3
Essential thrombocytaemia 9962/3 Other MPN MDS, AML, 9801/3–9809/3
Chronic neutrophilic leukaemia 9963/3 Other MPN, 9800/3, 9860/3 AML, 9801/3–9809/3
Chronic eosinophilic leukaemia, NOS 9964/3 Other MPN, 9800/3, 9860/3,9965/3,
9966/3, 9967/3
AML, 9801/3–9809/3
Myeloid and lymphoid neoplasms with
eosinophilia and
abnormalities of PDGFRA, PDGFRB or
FGFR1 (MNLE)
Myeloid and lymphoid neoplasms with PDGFRA
rearrangement
9965/3 MPN, 9800/3, 9820/3, 9860/3, 9964/3, AML, 9801/
3–9809/3
Myeloid neoplasms with PDGFRB rearrangement 9966/3 MPN, 9800/3, 9820/3, 9860/3, 9964/3, AML, 9801/
3–9809/3
Myeloid and lymphoid neoplasms with FGFR1
rearrangement
9967/3 MPN, PLN, 9800/3, 9820/3, 9860/3,
9964/3
AML, 9801/
3–9809/3
Myelodysplastic/myeloproliferative
neoplasms (MD/MPN)
Atypical chronic myeloid leukaemia, BCR-ABL1 negative 9876/3 Other MD/MPN, MDS, MPN; 9800/
3,
9860/3, 9863/3, 9960/3
AML, 9801/
3–9809/3
Chronic myelomonocytic leukaemia 9945/3 Other MD/MPN, MDS, 9800/3,
9860/3,
9863/3, 9960/3
AML, 9801/
3–9809/3
Juvenile myelomonocytic leukaemia 9946/3 Other MD/MPN, MDS, 9800/3,
9860/3,
9863/3, 9960/3
AML, 9801/
3–9809/3
Myelodysplastic/myeloproliferative neoplasm, unclassiﬁable 9975/3 Other MD/MPN, MDS, MPN AML, 9801/
3–9809/3
Myelodysplastic syndromes (MDS) Refractory anaemia 9980/3 Other MDS, 9945/3, 9975/3 AML, 9801/3,
9860/3
Refractory anaemia with ring sideroblasts 9982/3 Other MDS, 9945/3, 9975/3 AML, 9801/3,
9860/3
Refractory anaemia with excess blasts 9983/3 Other MDS, 9945/3, 9975/3 AML, 9801/3,
9860/3
Refractory cytopenia with multi-lineage dysplasia; Refractory
cytopenia of childhood
9985/3 Other MDS, 9945/3, 9975/3 AML, 9801/3,
9860/3
Myelodysplastic syndrome associated with isolated del(5q) 9986/3 Other MDS, 9945/3, 9975/3 AML, 9801/3,
9860/3
Myelodysplastic syndrome, NOS 9989/3 Other MDS, MD/MPN AML, 9801/3,
9860/3
Refractory neutropenia 9991/3 Other MDS, 9945/3, 9975/3 AML, 9801/3,
9860/3
Refractory thrombocytopenia 9992/3 Other MDS, 9945/3, 9975/3 AML, 9801/3,
9860/3
Acute myeloid leukaemia (AML) and
related precursor neoplasms.
Blastic plasmacytoid dendritic cell neoplasm (see note 4) 9727/3 Other AML, 9800/3–9809/3, 9860/3
Acute erythroid leukaemia 9840/3 Other AML, 9800/3–9809/3, 9860/3
Acute myeloid leukaemia, NOS 9861/3 Other AML, 9800/3–9809/3, 9860/3,
9965/3, 9966/3, 9967/3
(continued on next page)
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Appendix (continued)
Major subgroups according
to the World Health
Organisation (WHO)
Classiﬁcation
Initial diagnosis Morphology
code of the
ﬁrst HM
Major WHO subgroups and morphology codes
probably referring to the same tumour as the ﬁrst
HM (see note 3)
Major WHO subgroups and
morphology codes referring
to potential transformation of
the ﬁrst HM (see note 3)
Acute myeloid leukaemia with
t(6;9)(p23;q34); DEK-NUP214
9865/3 Other AML, 9800/3–9809/3, 9860/3
Acute promyelocytic leukaemia 9866/3 Other AML, 9800/3–9809/3, 9860/3
Acute myelomonocytic leukaemia 9867/3 Other AML, 9800/3–9809/3, 9860/3
Acute myeloid leukaemia with
inv(3)(q21q26.2) or t(3;3)(q21;q26.2);
RPN1-EVI1
9869/3 Other AML, 9800/3–9809/3, 9860/3
Acute basophilic leukaemia 9870/3 Other AML, 9800/3–9809/3, 9860/3
Acute myeloid leukaemia with
inv(16)(p13.1q22) or
t(16;16)(p13.1;q22) CBFB-MYH11
9871/3 Other AML, 9800/3–9809/3, 9860/3
Acute myeloid leukaemia with
minimal diﬀerentiation
9872/3 Other AML, 9800/3–9809/3, 9860/3
Acute myeloid leukaemia without
maturation
9873/3 Other AML, 9800/3–9809/3, 9860/3
Acute myeloid leukaemia with
maturation
9874/3 Other AML, 9800/3–9809/3, 9860/3
Acute monoblastic and monocytic
leukaemia
9891/3 Other AML, 9800/3–9809/3, 9860/3
Acute myeloid leukaemia with
myelodysplasia-related changes
9895/3 Other AML, 9800/3–9809/3, 9860/3
Acute myeloid leukaemia with
t(8;21)(q22;q22) RUNX1-RUNX1T1
9896/3 Other AML, 9800/3–9809/3, 9860/3
Acute myeloid leukaemia with
t(9;11)(p22;q23); MLLT3-MLL
9897/3 Other AML, 9800/3–9809/3, 9860/3
Myeloid leukaemia associated with
Down Syndrome
9898/3 Other AML, 9800/3–9809/3, 9860/3
Acute megakaryoblastic leukaemia 9910/3 Other AML, 9800/3–9809/3, 9860/3
Acute myeloid leukaemia
(megakaryoblastic) with
t(1;22)(p13;q13); RBM15-MKL1
9911/3 Other AML, 9800/3–9809/3, 9860/3
Therapy-related acute myeloid
leukaemia
9920/3 Other AML, 9800/3–9809/3, 9860/3; 9987/3
Myeloid sarcoma 9930/3 Other AML, 9800/3–9809/3, 9860/3
Acute panmyelosis with myeloﬁbrosis 9931/3 Other AML, 9800/3-9809/3, 9860/3, 9961/3
Refractory anaemia with excess blasts
in transition
9984/3 Other AML, 9800/3-9809/3, 9860/3
Therapy-related myelodysplastic
syndrome
9987/3 Other AML, MDS
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Precursor lymphoid
neoplasms (PLN)
B lymphoblastic lymphoma 9728/
3
Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/
3, 9687/3
T lymphoblastic lymphoma 9729/
3
Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9702/3
B lymphoblastic leukaemia/lymphoma, NOS 9811/
3
Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/
3, 9687/3
B lymphoblastic leukaemia/lymphoma with
t(9;22)(q34;q11.2); BCR-ABL1
9812/
3
Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/
3, 9687/3
B lymphoblastic leukaemia/lymphoma with t(v;11q23);
MLL rearranged
9813/
3
Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/
3, 9687/3
B lymphoblastic leukaemia/lymphoma with
t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)
9814/
3
Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/
3, 9687/3
B lymphoblastic leukaemia/lymphoma with
hyperdiploidy
9815/
3
Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/
3, 9687/3
B lymphoblastic leukaemia/lymphoma with
hypodiploidy (Hypodiploid ALL)
9816/
3
Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/
3, 9687/3
B lymphoblastic leukaemia/lymphoma with
t(5;14)(q31;q32); IL3-IGH
9817/
3
Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/
3, 9687/3
B lymphoblastic leukaemia/lymphoma with
t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)
9818/
3
Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/
3, 9687/3
Lymphoblastic leukaemia/lymphoma, NOS 9835/
3
Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/
3, 9687/3, 9702/3
B lymphoblastic leukaemia 9836/
3
Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9826/3, 9680/3, 9684/
3, 9687/3
T lymphoblastic leukaemia/lymphoma 9837/
3
Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9702/3
Mature B-cell neoplasms
(MBCN), indolent
Primary cutaneous follicle centre lymphoma 9597/
3
9590/3, 9591/3, 9690/3, 9691/3, 9695/3, 9698/3
Small lymphocytic lymphoma 9670/
3
9590/3, 9591/3, 9671/3, 9689/3, 9690/3, 9691/3, 9695/3, 9699/3, 9760/3,
9761/3, 9762/3, 9800/3, 9820/3, 9823/3, 9940/3
9680/3, 9650-9655/3, 9661-9667/
3
Chronic lymphocytic leukaemia 9823/
3
9590/3, 9591/3, 9670/3, 9671/3, 9689/3, 9690/3, 9691/3, 9695/3, 9699/3,
9800/3, 9820/3, 9940/3
9680/3, 9650-9655/3, 9661-9667/
3
Lymphoplasmacytic lymphoma 9671/
3
9590/3, 9591/3, 9670/3, 9760/3, 9761/3, 9762/3, PCN 9680/3, 9650-9655/3, 9661-9667/
3
Waldenstro¨m macroglobulinemia 9761/
3
9590/3, 9591/3, 9670/3, 9671/3, 9760/3, 9762/3, PCN 9680/3, 9650-9655/3, 9661-9667/
3
Splenic marginal zone lymphoma 9689/
3
9590/3, 9591/3, 9670/3, 9699/3 9680/3
Follicular lymphoma, NOS 9690/
3
9590/3, 9591/3, 9597/3, 9670/3, 9691/3, 9695/3, 9698/3 9680/3, 9687/3, 9826/3, 9836/3,
9728/3, 9811/3-9818/3
Follicular lymphoma, grade 2 9691/
3
9590/3, 9591/3, 9597/3, 9670/3, 9690/3, 9695/3, 9698/3 9680/3, 9687/3, 9826/3, 9836/3,
9728/3, 9811/3-9818/3
(continued on next page)
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Appendix (continued)
Major subgroups according
to the World Health
Organisation (WHO)
Classiﬁcation
Initial diagnosis Morphology
code of the
ﬁrst HM
Major WHO subgroups and morphology codes
probably referring to the same tumour as the ﬁrst
HM (see note 3)
Major WHO subgroups and
morphology codes referring
to potential transformation of
the ﬁrst HM (see note 3)
Follicular lymphoma, grade 1 9695/3 9590/3, 9591/3, 9597/3, 9670/3, 9690/3, 9691/3, 9698/3 9680/3, 9687/3, 9826/3, 9836/3, 9728/
3, 9811/3-9818/3
Marginal zone lymphoma 9699/3 9590/3, 9591/3, 9670/3, 9689/3 9680/3,
Heavy chain disease 9762/3 9590/3, 9591/3, 9670/3, 9671/3, 9760/3, 9761/3, PCN 9680/3,
Immunoproliferative small
intestinal disease
9764/3 9590/3, 9591/3,9760/3 9680/3
Hairy cell leukaemia 9940/3 9590/3, 9591/3, 9670/3, 9800/3, 9820/3, 9823/3 9680/3
Mature B-cell neoplasms (MBCN),
aggressive
Mantle cell lymphoma 9673/3 9590/3, 9591/3, 9596/3, 9675/3, 9680/3, 9800/3, 9820/3
Primary eﬀusion lymphoma 9678/3 9590/3, 9591/3, 9596/3, 9675/3, 9679/3, 9680/3, 9684/3, 9687/3,
9688/3, 9698/3, 9712/3, 9735/3, 9737/3, 9738/3
Primary mediastinal large B-cell
lymphoma
9679/3 9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9680/3, 9684/3, 9687/3,
9688/3, 9698/3, 9712/3, 9735/3, 9737/3, 9738/3
Diﬀuse large B-cell lymphoma 9680/3 9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9679/3, 9684/3, 9687/3,
9688/3, 9698/3, 9712/3, 9735/3, 9737/3, 9738/3
Diﬀuse large B-cell lymphoma,
immunoblastic
9684/3 9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9679/3, 9680/3, 9687/3,
9688/3, 9698/3, 9712/3, 9735/3, 9737/3, 9738/3
Burkitt lymphoma 9687/3 9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9679/3, 9680/3, 9684/3,
9688/3, 9698/3, 9800/3, 9801/3, 9820/3, 9826/3, 9712/3, 9735/3,
9737/3, 9738/3, 9835/3
T-cell/histiocyte rich large B-cell
lymphoma
9688/3 9590/3, 9591/3, 9596/3, 9678/3, 9679/3, 9680/3, 9684/3, 9687/3,
9698/3, 9675/3, 9712/3, 9735/3, 9737/3, 9738/3
Burkitt leukaemia 9826/3 9590/3, 9591/3, 9596/3, 9678/3, 9679/3, 9680/3, 9684/3, 9687/3,
9688/3, 9800/3, 9801/3, 9805/3-9809/3, 9820/3, 9712/3, 9735/3,
9737/3, 9738/3, 9835/3
Follicular lymphoma, grade 3 9698/3 9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9679/3, 9680/3, 9684/3,
9687/3, 9688/3, 9690/3, 9691/3, 9695/3, 9712/3, 9735/3, 9737/3,
9738/3, 9597/3
Intravascular large B-cell
lymphoma (C49.9)
9712/3 9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9679/3, 9680/3, 9684/3,
9687/3, 9688/3, 9698/3, 9735/3, 9737/3, 9738/3
Plasmablastic lymphoma 9735/3 9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9679/3, 9680/3, 9684/3,
9687/3, 9688/3, 9698/3, 9712/3, 9737/3, 9738/3, PCN
ALK positive large B-cell
lymphoma
9737/3 9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9679/3, 9680/3, 9684/3,
9687/3, 9688/3, 9698/3, 9712/3, 9735/3, 9738/3
Large B-cell lymphoma arising in
HHV8-associated multicentric
Castleman disease
9738/3 9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9679/3, 9680/3, 9684/3,
9687/3, 9688/3, 9698/3, 9712/3, 9735/3, 9737/3
B-cell prolymphocytic
leukaemia
9833/3 9590/3, 9591/3, 9800/3, 9820/3, 9823/3, 9832/3
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Mature B-cell
neoplasms, plasma cell
neoplasms (PCN)
Solitary plasmacytoma of bone 9731/3 9671/3, 9734/3, 9735/3, 9761/
3, 9762/3
9732/3; 9733/3
Plasma cell myeloma 9732/3 9671/3, 9731/3, 9734/3, 9735/
3, 9761/3, 9762/3
9733/3
Plasma cell leukaemia 9733/3 9671/3, 9731/3, 9732/3, 9734/
3, 9735/3, 9761/3, 9762/3,
9800/3, 9801/3, 9820/3,
Extraosseous plasmacytoma 9734/3 9671/3, 9731/3, 9735/3, 9761/
3, 9762/3
9732/3; 9733/3
Mature T-cell and NK-
cell neoplasms (MTCN)
Mycosis fungoides 9700/3 Other MTCN (excl. 9702/3),
9590/3, 9591/3
9702/3, 9727/3,
9729/3, 9835/3,
9837/3
Se´zary syndrome 9701/3 Other MTCN, 9590/3, 9591/
3
(Peripheral) T-cell lymphoma, NOS 9702/3 Other MTCN, 9590/3, 9591/
3, 9727/3, 9729/3, 9835/3,
9837/3
Angioimmunoblastic T-cell lymphoma 9705/3 Other MTCN, 9590/3, 9591/
3
Subcutaneous panniculitis-like T-cell
lymphoma
9708/3 Other MTCN, 9590/3, 9591/
3
Cutaneous T-cell lymphoma, NOS 9709/3 Other MTCN (excl. 9702/3),
9590/3, 9591/3
9702/3, 9727/3,
9729/3, 9835/3,
9837/3
Anaplastic large cell lymphoma, ALK
positive
9714/3 Other MTCN, 9590/3, 9591/
3
Hepatosplenic T-cell lymphoma 9716/3 Other MTCN, 9590/3, 9591/
3
Enteropathy-associated T-cell
lymphoma
9717/3 Other MTCN, 9590/3, 9591/
3
Primary cutaneous anaplastic large cell
lymphoma
9718/3 Other MTCN, 9590/3, 9591/
3
Extranodal NK/T-cell lymphoma, nasal
type
9719/3 Other MTCN, 9590/3, 9591/
3
Systemic EBV positive T-cell
lymphoproliferative disease of
childhood
9724/3 Other MTCN, 9590/3, 9591/
3
Hydroavacciniforme-like lymphoma 9725/3 Other MTCN, 9590/3, 9591/
3
Primary cutaneous gamma-delta T-cell
lymphoma
9726/3 Other MTCN, 9590/3, 9591/
3
Adult T-cell leukaemia/lymphoma 9827/3 Other MTCN, 9800/3, 9801/
3, 9805/3-9809/3, 9820/3
(continued on next page)
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Appendix (continued)
Major subgroups
according
to the World Health
Organisation
(WHO)
Classiﬁcation
Initial diagnosis Morphology
code of the ﬁrst
HM
Major WHO subgroups and morphology codes probably
referring to the same tumour as the ﬁrst HM (see note 3)
Major WHO subgroups and
morphology codes referring
to potential transformation of
the ﬁrst HM (see note 3)
T-cell large granular lymphocytic
leukaemia
9831/3 Other MTCN, 9590/3, 9591/3, 9800/3, 9820/3, 9832/3
T-cell prolymphocytic leukaemia 9834/3 Other MTCN, 9590/3, 9591/3, 9800/3, 9820/3, 9832/3
Aggressive NK-cell leukaemia 9948/3 Other MTCN, 9800/3, 9801/3, 9805/3-8909/3, 9820/3
Hodgkin lymphoma
(HL)
Hodgkin lymphoma, NOS 9650/3 Other HL, 9590/3, 9596/3
Lymphocyte-rich classical
Hodgkin lymphoma
9651/3 Other HL, 9590/3, 9596/3
Mixed cellularity classical
Hodgkin lymphoma
9652/3 Other HL, 9590/3, 9596/3
Lymphocyte-depleted classical
Hodgkin lymphoma
9653/3 Other HL, 9590/3, 9596/3
Lymphocyte-depleted classical
Hodgkin lymphoma, diﬀuse
ﬁbrosis
9654/3 Other HL, 9590/3, 9596/3
Lymphocyte-depleted classical
Hodgkin lymphoma, reticular
9655/3 Other HL, 9590/3, 9596/3
Nodular lymphocyte predominant
Hodgkin lymphoma
9659/3 Other HL, 9590/3, 9596/3 9680/3
Hodgkin granuloma 9661/3 Other HL, 9590/3, 9596/3
Hodgkin sarcoma 9662/3 Other HL, 9590/3, 9596/3
Nodular sclerosis classical
Hodgkin lymphoma
9663/3 Other HL, 9590/3, 9596/3
Nodular sclerosis classical
Hodgkin lymphoma, cellular
phase
9664/3 Other HL, 9590/3, 9596/3
Nodular sclerosis classical
Hodgkin lymphoma, grade 1
9665/3 Other HL, 9590/3, 9596/3
Nodular sclerosis classical
Hodgkin lymphoma, grade 2
9667/3 Other HL, 9590/3, 9596/3
Histiocytic and dendritic
cell neoplasms (HDCN)
Malignant histiocytosis, NOS 9750/3 Other HDCN
Langerhans cell histiocytosis 9751/3 Other HDCN
Langerhans cell histiocytosis,
unifocal
9752/1 Other HDCN (see note 2)
Langerhans cell histiocytosis,
multifocal
9753/1 Other HDCN (see note 2)
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Langerhans cell histiocytosis, disseminated 9754/3 Other HDCN (see note 2)
Histiocytic sarcoma 9755/3 Other HDCN
Langerhans cell sarcoma 9756/3 Other HDCN
Interdigitating dendritic cell sarcoma; intermediate
dendritic cell tumour
9757/3 Other HDCN
Follicular dendritic cell tumour 9758/3 Other HDCN
Fibroblastic reticular cell tumour 9759/3 Other HDCN
Unspeciﬁed/mixed
neoplasms
Lymphoma, NOS 9590/3 HL, MBCN, MTCN, PLN
Non-Hodgkin lymphoma, NOS 9591/3 MBCN, MTCN, PLN, 959
Mixed Hodgkin lymphoma and non-Hodgkin lymphoma 9596/3 HL, MBCN, MTCN, PLN
Malignant lymphoma, mixed small and large cell, diﬀuse 9675/3 MBCN, MTCN, PLN, 959
Immunoproliferative disease, NOS 9760/3 MBCN, 9590/3, 9591/3
Leukaemia, NOS 9800/3 9670/3, 9673/3, 9733/3, 974
Acute undiﬀerentiated leukaemia; acute leukaemia, NOS 9801/3 9733/3, 9800/3, 9805/3, 980
9965/3 9966/3, PLN, AML
Mixed phenotype acute leukaemia, NOS 9805/3 9800/3, 9801/3, 9806/3, 980
PLN, AML
Mixed phenotype acute leukaemia with
t(9;22)(q34;q11.2); BCR-ABL1
9806/3 9800/3, 9801/3, 9805/3, 9807
Mixed phenotype acute leukaemia with t(v;11q23); MLL
rearranged
9807/3 9800/3, 9801/3, 9805/3, 980
Mixed phenotype acute leukaemia, B/myeloid, NOS 9808/3 9800/3, 9801/3, 9805/3, 980
Mixed phenotype acute leukaemia, T/myeloid, NOS 9809/3 9800/3, 9801/3, 9805/3, 980
Lymphocytic leukaemia, NOS 9820/3 9670/3, 9673/3, 9733/3, 980
3, 9967/3, PLN
Prolymphocytic leukaemia, NOS 9832/3 9800/3, 9820/3, 9833/3, 983
Myeloid leukaemia, NOS 9860/3 9742/3, 9800/3, 9801/3, 9805
3, 9967/3
Note 1. In systemic mastocytosis (SM) a coexisting haematological neoplasm may be present (SM-AHNMD). Then, the disease m
haematological non-mast cell lineage disorder (MDS, MPN, AML, lymphoma or other haematological neoplasm that meet the c
progress/transform to acute leukaemia.
Note 2. Langerhans cell histiocytosis, irrespective of the degree of dissemination, was reclassiﬁed from /1 to /3 in the 4th edition o
Note 3. Even if the morphology codes mentioned in this table refer to the same tumour or to a transformation, there may be clini
tumours should be registered. For example, if a patient has a diagnosis of myeloma and a diagnosis of lymphoplasmocytic lymphoma
diﬀerent diseases if there is clinical evidence for the latter, based on the type of immunoglobulins.
Note 4. Morphology code 9727 was used for ‘Precursor cell lymphoblastic lymphoma, NOS’ in ICD-O-3, while according to the
plasmocytoid dendritic cell neoplasm., 9591/3, 9596/3, 9760/3
0/3, 9596/3,9760/3
, 9590/3, 9591/3
0/3, 9591/3
2/3, 9801/3-9948/3, 9963, 9964, 9965/3, 9966/3, 9967/3
6/3, 9807/3, 9808/3, 9809/3, 9820/3, 9826/3, 9827/3, , 9948/3,
7/3, 9808/3, 9809/3, 9820/3, 9826/3, 9827/3, 9860/3, , 9948/3,
/3, 9808/3, 9809/3, 9820/3, 9826/3, 9827/3, , 9948/3, PLN, AML
6/3, 9808/3, 9809/3, 9820/3, 9826/3, 9827/3, 9948/3, PLN, AML
6/3, 9807/3, 9809/3, 9820/3, 9826/3, 9827/3, 9948/3, PLN, AML
6/3, 9807/3, 9808/3, 9820/3, 9826/3, 9827/3, 9948/3, PLN, AML
0/3, 9801/3, 9805/3-9809/3, 9823/3-9834/3, 9940/3, 9965/3, 9966/
4/3
/3, 9840/3-9931/3, 9945/3, 9946/3, 9963/3, 9964/3, 9965/3, 9966/
eets the criteria for SM and the criteria for an associated, clonal
riteria for a distinct entity in the WHO classiﬁcation). This may
f the WHO Classiﬁcation.
cal evidence for a second tumour. In those (often rare) cases two
, they may be considered as one disease, but they may also be two
2011 ICD-O-3 Update this morphology code is used for ‘Blastic
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